Table 1.
Clinical trials for cancer therapies involving ARID1A
| Number | Study types | Status | Phase | Cancer types | Intervention | Primary endpoint |
|---|---|---|---|---|---|---|
| NCT04065269 | Interventional (Clinical Trial) | Recruiting | II | Gynecological Cancers | ATR inhibitor (AZD6738), PARP inhibitor (Olaparib) | ORR |
| NCT04957615 | Interventional (Clinical Trial) | Recruiting | II | Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm | Nivolumab | ORR, OS |
| NCT05523440 | Interventional (Clinical Trial) | Recruiting | II |
Recurrent Endometrial Carcinoma Recurrent Ovarian Carcinoma |
Bevacizumab, Niraparib | ORR |
| NCT05690035 | Interventional (Clinical Trial) | Not yet recruiting | II | Metastatic Colorectal Cancer | Tislelizumab & Fruquintinib | ORR |
| NCT04953104 | Interventional (Clinical Trial) | Not yet recruiting | II | Urologic Neoplasms | Nivolumab | ORR, OS |
| NCT03682289 | Interventional (Clinical Trial) | Recruiting | II | Solid Tumors | Ceralasertib, Olaparib, Durvalumab | ORR |
| NCT04042831 | Interventional (Clinical Trial) | Recruiting | II | Advanced Biliary Tract Cancer | Olaparib | ORR |
| NCT04284202 | Interventional (Clinical Trial) | Unknown | II | NSCLC Stage IV | PD-1 plus Dasatinib | PFS |
ATR: ataxia telangiectasia and rad3-related; PARP: poly (ADP-ribose) polymerase; PD-1: Programmed cell death protein 1; ORR: Objective Response Rate; OS: overall survival; PFS: Progress Free Survival